These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 30568427)

  • 41. The effect of N-acetylcysteine in patients with non-cystic fibrosis bronchiectasis (NINCFB): study protocol for a multicentre, double-blind, randomised, placebo-controlled trial.
    Liao Y; Wu Y; Zi K; Shen Y; Wang T; Qin J; Chen L; Chen M; Liu L; Li W; Zhou H; Xiong S; Wen F; Chen J
    BMC Pulm Med; 2022 Nov; 22(1):401. PubMed ID: 36344940
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Airway Bacterial Load and Inhaled Antibiotic Response in Bronchiectasis.
    Sibila O; Laserna E; Shoemark A; Keir HR; Finch S; Rodrigo-Troyano A; Perea L; Lonergan M; Goeminne PC; Chalmers JD
    Am J Respir Crit Care Med; 2019 Jul; 200(1):33-41. PubMed ID: 31109172
    [No Abstract]   [Full Text] [Related]  

  • 43. Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa.
    Antonela Antoniu S
    Expert Rev Anti Infect Ther; 2012 Dec; 10(12):1439-46. PubMed ID: 23253321
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhaled antibiotics for lower respiratory tract infections: focus on ciprofloxacin.
    Serisier DJ
    Drugs Today (Barc); 2012 May; 48(5):339-51. PubMed ID: 22645722
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.
    Flume PA; VanDevanter DR; Morgan EE; Dudley MN; Loutit JS; Bell SC; Kerem E; Fischer R; Smyth AR; Aaron SD; Conrad D; Geller DE; Elborn JS
    J Cyst Fibros; 2016 Jul; 15(4):495-502. PubMed ID: 26852040
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeted AntiBiotics for Chronic pulmonary diseases (TARGET ABC): can targeted antibiotic therapy improve the prognosis of Pseudomonas aeruginosa-infected patients with chronic pulmonary obstructive disease, non-cystic fibrosis bronchiectasis, and asthma? A multicenter, randomized, controlled, open-label trial.
    Eklöf J; Alispahic IA; Sivapalan P; Wilcke T; Seersholm N; Armbruster K; Kjærgaard JL; Saeed MI; Nielsen TL; Browatzki A; Overgaard RH; Fenlev CS; Harboe ZB; Andreassen HF; Lapperre TS; Pedersen L; Johnsen S; Ulrik CS; Janner J; Moberg M; Heidemann M; Weinreich UM; Vijdea R; Linde H; Titlestad I; Johansson SL; Rosenvinge FS; Østergaard C; Ghathian KSA; Gundersen L; Christensen CW; Bangsborg J; Jensen TT; Sørensen VM; Ellingsgaard T; Datcu R; Coia JE; Bodtger U; Jensen JUS
    Trials; 2022 Sep; 23(1):817. PubMed ID: 36167555
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibiotic therapy for stable non-CF bronchiectasis in adults - A systematic review.
    Fjaellegaard K; Sin MD; Browatzki A; Ulrik CS
    Chron Respir Dis; 2017 May; 14(2):174-186. PubMed ID: 27507832
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection.
    Haworth CS; Foweraker JE; Wilkinson P; Kenyon RF; Bilton D
    Am J Respir Crit Care Med; 2014 Apr; 189(8):975-82. PubMed ID: 24625200
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis.
    Wilson R; Aksamit T; Aliberti S; De Soyza A; Elborn JS; Goeminne P; Hill AT; Menendez R; Polverino E
    Respir Med; 2016 Aug; 117():179-89. PubMed ID: 27492530
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Management of Non-Cystic Fibrosis Bronchiectasis.
    Dull SK; Havlat BD; Sanley MJ; Malesker MA
    Consult Pharm; 2018 Nov; 33(11):658-666. PubMed ID: 30458908
    [No Abstract]   [Full Text] [Related]  

  • 51. Inhaled antibiotics in the treatment of non-cystic fibrosis bronchiectasis: clinical and drug delivery perspectives.
    Sugianto TD; Chan HK
    Expert Opin Drug Deliv; 2016; 13(1):7-22. PubMed ID: 26289675
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Results of Tobramycin Inhalation Therapy in Patients with Noncystic Fibrosis Bronchiectasis with
    Tanriverdi E; Yildirim BZ; Gul S; Chousein EGU; Turan D; Çınarka H; Özgül MA; Cetinkaya E
    J Aerosol Med Pulm Drug Deliv; 2021 Sep; 34(5):274-279. PubMed ID: 33351705
    [No Abstract]   [Full Text] [Related]  

  • 53. Macrolide Treatment Inhibits Pseudomonas aeruginosa Quorum Sensing in Non-Cystic Fibrosis Bronchiectasis. An Analysis from the Bronchiectasis and Low-Dose Erythromycin Study Trial.
    Burr LD; Rogers GB; Chen AC; Hamilton BR; Pool GF; Taylor SL; Venter D; Bowler SD; Biga S; McGuckin MA
    Ann Am Thorac Soc; 2016 Oct; 13(10):1697-1703. PubMed ID: 27464029
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhaled steroids for bronchiectasis.
    Kapur N; Bell S; Kolbe J; Chang AB
    Cochrane Database Syst Rev; 2009 Jan; (1):CD000996. PubMed ID: 19160186
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel Inhalable Ciprofloxacin Dry Powders for Bronchiectasis Therapy: Mannitol-Silk Fibroin Binary Microparticles with High-Payload and Improved Aerosolized Properties.
    Liu C; Lin L; Huang Z; Wu Q; Jiang J; Lv L; Yu X; Quan G; Li G; Wu C
    AAPS PharmSciTech; 2019 Jan; 20(2):85. PubMed ID: 30673901
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Investigational inhaled therapies for non-CF bronchiectasis.
    Antoniu SA
    Expert Opin Investig Drugs; 2018 Feb; 27(2):139-146. PubMed ID: 29338445
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhaled hyperosmolar agents for bronchiectasis.
    Hart A; Sugumar K; Milan SJ; Fowler SJ; Crossingham I
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD002996. PubMed ID: 24817558
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New therapeutic options for noncystic fibrosis bronchiectasis.
    Yap VL; Metersky ML
    Curr Opin Infect Dis; 2015 Apr; 28(2):171-6. PubMed ID: 25692269
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1).
    Loebinger MR; Polverino E; Blasi F; Elborn SJ; Chalmers JD; Tiddens HA; Goossens H; Tunney M; Zhou W; Angyalosi G; Hill AT; Haworth CS;
    Pulm Pharmacol Ther; 2019 Oct; 58():101834. PubMed ID: 31433997
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis.
    Barker AF; Couch L; Fiel SB; Gotfried MH; Ilowite J; Meyer KC; O'Donnell A; Sahn SA; Smith LJ; Stewart JO; Abuan T; Tully H; Van Dalfsen J; Wells CD; Quan J
    Am J Respir Crit Care Med; 2000 Aug; 162(2 Pt 1):481-5. PubMed ID: 10934074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.